BPC-157 · research summary

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.

International journal of molecular sciences · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

In vitro enzyme kinetics and molecular docking study
“The present study aimed to investigate, for the first time, the inhibitory effects of BPC-157 on acetylcholinesterase activity and to compare its activity with that of newly designed hybrid analogs, CIARA-1 and CIARA-2, using kinetic analysis.”

Subjects

Human acetylcholinesterase (AChE) and three peptides: BPC-157, CIARA-1, and CIARA-2
“Human acetylcholinesterase was used at a final concentration of 0.01 U/mL in the reaction mixture.”

Sample size

Six independent experiments (n = 6)
“All experiments were performed in six independent repetitions (n = 6), and the obtained results are expressed as mean ± standard deviation (SD).”

Duration

5 minutes per reaction measurement
“The reaction was initiated by adding AChE, and absorbance changes were monitored continuously at 412 nm for 5 min.”

Reported findings

All tested compounds exhibited a competitive mechanism of inhibition
“All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis–Menten constant (Km) values with unchanged maximum velocity (Vmax), indicating competition with the substrate at the catalytic site of AChE.”
CIARA-1 demonstrated the highest inhibitory potency among the tested peptides
“Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (Ki = 0.24 mM) and IC50 value (2.52 mM), followed by CIARA-2 (Ki = 0.29 mM; IC50 = 2.73 mM) and BPC-157 (Ki = 0.48 mM; IC50 = 2.80 mM).”
Molecular docking results supported the experimental findings of competitive binding
“The results clearly indicate that all investigated peptides bind preferentially to the enzyme conformation represented by the competitive model (PDB: 4EY6), consistent with the inhibition mechanism derived from kinetic analysis.”

Limitations stated by the authors

In vitro conditions do not reflect physiological complexity, and peptide stability and blood-brain barrier permeability were not assessed
“The experiments were conducted under in vitro conditions using purified enzyme systems, which do not fully reflect physiological complexity.”

Source: PubMed 42278509 · DOI 10.3390/ijms27114984 · all study summaries

Study type

In vitro enzyme kinetics and molecular docking study

“The present study aimed to investigate, for the first time, the inhibitory effects of BPC-157 on acetylcholinesterase activity and to compare its activity with that of newly designed hybrid analogs, CIARA-1 and CIARA-2, using kinetic analysis.”

Reported findings

All tested compounds exhibited a competitive mechanism of inhibition

“All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis–Menten constant (Km) values with unchanged maximum velocity (Vmax), indicating competition with the substrate at the catalytic site of AChE.”

CIARA-1 demonstrated the highest inhibitory potency among the tested peptides

“Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (Ki = 0.24 mM) and IC50 value (2.52 mM), followed by CIARA-2 (Ki = 0.29 mM; IC50 = 2.73 mM) and BPC-157 (Ki = 0.48 mM; IC50 = 2.80 mM).”

Molecular docking results supported the experimental findings of competitive binding

“The results clearly indicate that all investigated peptides bind preferentially to the enzyme conformation represented by the competitive model (PDB: 4EY6), consistent with the inhibition mechanism derived from kinetic analysis.”